Armata Pharmaceuticals, Inc.
ARMP- Exchange
- NYSE
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000921114
No open-market purchases or sales by Armata Pharmaceuticals, Inc. insiders were filed in the last 90 days; 53 institutions reported holding it in 13F filings for Q2 2026, worth $32.3M in total; no superinvestor holds it.
13F holders, Q1 2025
Institutional positions in Armata Pharmaceuticals, Inc. as of Mar 31, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 26
- +2 vs. Q4 2024
- Shares held
- 741.8K
- −648.5K (−46.6%) vs. Q4 2024
- Total value
- $1.08M
- −$1.49M (−57.9%) vs. Q4 2024
- New holders
- 2
- 2 more added
- Sold out
- 0
- 9 more reduced
Compare with Q4 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ARMP on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 53 | $32.3M |
| Q1 2026 | 45 | $40.2M |
| Q4 2025 | 36 | $7.85M |
| Q3 2025 | 28 | $2.27M |
| Q2 2025 | 29 | $1.40M |
| Q1 2025 | 26 | $1.08M |
| Q4 2024 | 24 | $2.57M |
| Q3 2024 | 24 | $3.28M |
| Q2 2024 | 23 | $3.86M |
| Q1 2024 | 24 | $5.93M |
| Q4 2023 | 25 | $4.17M |
| Q3 2023 | 23 | $3.85M |
| Q2 2023 | 22 | $1.35M |
| Q1 2023 | 23 | $2.06M |
| Q4 2022 | 26 | $1.61M |
| Q3 2022 | 20 | $5.73M |
| Q2 2022 | 19 | $5.25M |
| Q1 2022 | 20 | $6.61M |
| Q4 2021 | 17 | $7.25M |
| Q3 2021 | 20 | $4.32M |
| Q2 2021 | 21 | $4.59M |
| Q1 2021 | 23 | $5.62M |
Institutions, Q1 2025
Shares, value and share of portfolio for each institution holding Armata Pharmaceuticals, Inc.; share changes are against Q4 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Wells Fargo & Company | 1 | $1 | 0.00% | 00.0% | Unchanged |
| SBI Securities Co., Ltd. | 3 | $4 | 0.00% | 00.0% | Unchanged |
| JPMorgan Chase & Co | 22 | $32 | 0.00% | −3−12.0% | Reduced |
| MAI Capital Management | 71 | $104 | 0.00% | 00.0% | Unchanged |
| Bank of America Corp | 93 | $136 | 0.00% | −633,939−100.0% | Reduced |
| Salem Investment Counselors Inc | 100 | $146 | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 109 | $159 | 0.00% | 00.0% | Unchanged |
| Advisor Group Holdings, Inc. | 357 | $521 | 0.00% | +357 | New |
| Northwestern Mutual Wealth Management Co | 571 | $834 | 0.00% | 00.0% | Unchanged |
| Trifecta Capital Advisors, LLC | 714 | $1.04K | 0.00% | 00.0% | Unchanged |
| Cornerstone National Bank & Trust Co | 1,428 | $2.08K | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 1,746 | $2.55K | 0.00% | −4,567−72.3% | Reduced |
| Tower Research Capital LLC (TRC) | 3,471 | $5.07K | 0.00% | +159+4.8% | Added |
| Group One Trading, L.P. | 4,798 | $7.00K | 0.00% | −6,816−58.7% | Reduced |
| Captrust Financial Advisors | 13,140 | $19.2K | 0.00% | 00.0% | Unchanged |
| Northern Trust Corp | 19,273 | $28.1K | 0.00% | 00.0% | Unchanged |
| Citadel Advisors LLC | 20,594 | $30.1K | 0.00% | +20,594 | New |
| BlackRock, Inc. | 23,184 | $33.8K | 0.00% | −441−1.9% | Reduced |
| Susquehanna International Group, LLP | 27,681 | $40.4K | 0.00% | −22,107−44.4% | Reduced |
| SeaCrest Wealth Management, LLC | 34,954 | $51.0K | 0.01% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 38,596 | $56.4K | 0.00% | −1,695−4.2% | Reduced |
| State Street Corp | 40,300 | $58.8K | 0.00% | 00.0% | Unchanged |
| Bridgeway Capital Management, LLC | 44,682 | $65.2K | 0.00% | −25,000−35.9% | Reduced |
| Edgewood Management LLC | 100,000 | $146.0K | 0.00% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 105,837 | $154.6K | 0.00% | −952−0.9% | Reduced |
| Vanguard Group Inc | 260,073 | $379.7K | 0.00% | +25,954+11.1% | Added |